Genetic Testing for Alström Syndrome: A Parent's Guide

Genetic testing is how Alström Syndrome is confirmed. The test looks at the ALMS1 gene for changes that disrupt the protein it makes. This article explains what's actually being tested, how the test is ordered, what the report will tell you, what insurance and access look like, and what to do with the results.

The ALMS1 gene sits on chromosome 2 and contains 23 exons (the coding regions that build the protein). Pathogenic changes in ALMS1 are most often nonsense or frameshift mutations that result in a truncated, non-functional protein. Hotspots cluster around exons 8, 10, and 16.¹

A diagnostic genetic test for Alström looks for two such changes — one inherited from each parent, since Alström is autosomal recessive. The test confirms the diagnosis when two pathogenic variants are identified.

Targeted ALMS1 sequencing

The most direct route when Alström is strongly suspected. The lab sequences all 23 exons plus the splice junctions and reports any variants found. Some panels also test for larger deletions and duplications that sequencing alone can miss.

Multi-gene panels

Panels for inherited retinal dystrophies, ciliopathies, or pediatric cardiomyopathies typically include ALMS1 alongside dozens of related genes. Multi-gene panels are useful when:

• The clinical picture isn't fully developed
• Several conditions are in the differential (Bardet-Biedl, Usher, Leber)
• Ordering several targeted tests would be slower or more expensive

Whole-exome / whole-genome sequencing

Used when:

• Targeted panels haven't found an answer
• The clinical picture is unusual or atypical
• Critical illness in a NICU/PICU baby calls for the broadest possible test

Most genetic testing is ordered by:

• A clinical geneticist
• A pediatric subspecialist (cardiologist, ophthalmologist, neurologist) familiar with the testing process
• A genetic counselor

The process typically involves:

1. Pre-test counseling — explaining what the test can and cannot tell you, and the implications for family 2. Sample collection — usually a blood draw or buccal (cheek) swab 3. Lab processing — typically 2–6 weeks 4. Post-test counseling — discussion of results, next steps, and family planning implications

Genetic test reports use standardized terminology to describe each variant found:²

• Pathogenic — known to cause disease
• Likely pathogenic — probably causes disease, with strong supporting evidence
• Variant of uncertain significance (VUS) — meaning unclear; needs further evidence
• Likely benign — probably doesn't cause disease
• Benign — known not to cause disease

A confirmed Alström diagnosis usually requires two pathogenic or likely pathogenic variants in ALMS1. If the report shows two such variants, the diagnosis is made.

If the report shows only one pathogenic variant and one VUS, your geneticist will likely:

• Order parental testing to see who carries which variant (segregation analysis)
• Re-analyze the test in 6–12 months as new variant data accumulates
• Consider further testing for deletions/duplications

If only one pathogenic variant is found and no second variant is identified, the gene may need different testing modalities (deletion/duplication analysis, intronic sequencing) — see our misdiagnosis article.

In the US, genetic testing for suspected Alström is generally covered by major insurers when there's a documented clinical reason and the test is ordered by an appropriate specialist. Pre-authorization is sometimes required.

In the UK, the NHS funds genetic testing through NHS Genomic Medicine Service test directories, and ALMS1 testing is included for clinically appropriate cases.

Lab costs vary widely — sometimes US$300–3,000 for a panel, sometimes more for whole-exome sequencing. Patient-assistance programs through the major commercial labs (Invitae, GeneDx, Blueprint Genetics, others) can reduce or waive costs in financial hardship cases.

A confirmed ALMS1 diagnosis triggers several next steps:

1. Coordinate baseline studies in every system Alström can affect — see first steps after diagnosis. 2. Schedule genetic counseling for the family. Family members may want carrier testing. 3. Discuss recurrence risk — 25% in each future pregnancy if both parents are confirmed carriers. 4. Consider testing for siblings — particularly if any have potentially relevant features. 5. Notify your child's pediatrician and any other treating clinicians so they can incorporate the diagnosis into ongoing care.

If your child has features strongly suggestive of Alström but the targeted test is negative:

• Confirm what was tested. Was it sequencing only, or was deletion/duplication analysis included?
• Ask about expanded testing — broader ciliopathy panel or whole-exome sequencing
• Re-analyze stored data in 12 months as variant databases grow
• Continue surveillance of the systems involved while testing continues

A truly negative result (sequencing plus deletion/duplication analysis fully covered, plus no Alström features that don't fit another diagnosis) makes Alström unlikely but doesn't rule it out completely. Many ciliopathies share features.

• Alström Syndrome Diagnosis Hub
• How Is Alström Syndrome Diagnosed?
• The ALMS1 Gene & Alström Syndrome Genetics
• What Is the ALMS1 Gene?
• ALMS1 Mutations: Understanding Your Genetic Test Report
• Variants of Uncertain Significance in Alström Testing

April 30, 2026.